Impax Laboratories Inc. (NASDAQ:IPXL) had its target price cut by equities research analysts at Royal Bank Of Canada from $30.00 to $18.00 in a research note issued on Thursday. The firm currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 20.00% […]
